The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.
 
Suzanne Trudel
Honoraria - Amgen; Forus; GlaxoSmithKline; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Janssen; K36 therapeutics; Pfizer; Roche
 
Meral Beksac
Consulting or Advisory Role - BMS Turkey (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Oncopeptides (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst)
Speakers' Bureau - BMS Turkey (Inst); Menarini (Inst); Sanofi (Inst); Takeda (Inst)
 
Ludek Pour
No Relationships to Disclose
 
Sosana Delimpasi
Honoraria - Amgen; GlaxoSmithKline; Janssen; Takeda
 
Hang Quach
Consulting or Advisory Role - Antengene (Inst); Bristol-Myers Squibb/Celgene; GlaxoSmithKline (Inst); Janssen-Cilag; Karyopharm Therapeutics (Inst); Pfizer; Roche; Sanofi (Inst)
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi
 
Vladimir Vorobyev
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Gilead Sciences; Janssen; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Gilead Sciences; Janssen Oncology; Novartis; Roche; Sanofi; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; BeiGene; BioCad; BMSi; Janssen; MSD; Novartis; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - AstraZeneca
 
Michele Cavo
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Celgene/Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini Group; Sanofi; Takeda
Consulting or Advisory Role - Amgen, AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Menarini Stemline, Sanofi, and Karyopharm Therapeutics
Speakers' Bureau - Celgene/Bristol-Myers Squibb; Janssen
 
Kazuhito Suzuki
Honoraria - Bristol-Myers Squibb; Janssen; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Janssen; Sanofi
 
Pawel Robak
No Relationships to Disclose
 
Kristin Morris
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Chee Paul Lin
Employment - GlaxoSmithKline
 
Ianire Garrobo-Calleja
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Giulia Fulci
Employment - GlaxoSmithKline
 
Elisabet Manasanch
Employment - GlaxoSmithKline
 
Brandon Kremer
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Maria-Victoria Mateos
Honoraria - Abbvie/Genentech; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Kite, a Gilead company; Pfizer; Regeneron; Roche/Genentech; Stemline Therapeutics; Takeda
 
Meletios Dimopoulos
Honoraria - Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Menarini; Regeneron; Sanofi; Swixx BioPharma; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Menarini; Regeneron; Sanofi; Swixx BioPharma; Takeda
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; Janssen; Takeda